An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Related Research units
Abstract
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of
Bibliographical data
| Original language | German |
|---|---|
| ISSN | 0145-2126 |
| Publication status | Published - 2009 |
| pubmed | 19674789 |
|---|
